company background image
CYCN

Cyclerion Therapeutics NasdaqGS:CYCN Stock Report

Last Price

US$0.56

Market Cap

US$24.5m

7D

-5.8%

1Y

-80.8%

Updated

15 May, 2022

Data

Company Financials +
CYCN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

CYCN Stock Overview

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases.

Cyclerion Therapeutics Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Cyclerion Therapeutics
Historical stock prices
Current Share PriceUS$0.56
52 Week HighUS$4.86
52 Week LowUS$0.50
Beta1.84
1 Month Change-43.50%
3 Month Change-50.87%
1 Year Change-80.78%
3 Year Change-96.13%
5 Year Changen/a
Change since IPO-95.48%

Recent News & Updates

Shareholder Returns

CYCNUS BiotechsUS Market
7D-5.8%0.1%-2.5%
1Y-80.8%-21.7%-10.4%

Return vs Industry: CYCN underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: CYCN underperformed the US Market which returned -10.4% over the past year.

Price Volatility

Is CYCN's price volatile compared to industry and market?
CYCN volatility
CYCN Average Weekly Movement11.9%
Biotechs Industry Average Movement12.3%
Market Average Movement7.8%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: CYCN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: CYCN's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201832Peter Hechthttps://www.cyclerion.com

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS.

Cyclerion Therapeutics Fundamentals Summary

How do Cyclerion Therapeutics's earnings and revenue compare to its market cap?
CYCN fundamental statistics
Market CapUS$24.55m
Earnings (TTM)-US$51.23m
Revenue (TTM)US$4.59m

5.3x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CYCN income statement (TTM)
RevenueUS$4.59m
Cost of RevenueUS$35.34m
Gross Profit-US$30.75m
Other ExpensesUS$20.48m
Earnings-US$51.23m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.18
Gross Margin-669.81%
Net Profit Margin-1,115.79%
Debt/Equity Ratio0.0%

How did CYCN perform over the long term?

See historical performance and comparison

Valuation

Is Cyclerion Therapeutics undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


0.66x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CYCN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CYCN's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: CYCN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CYCN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CYCN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CYCN is good value based on its PB Ratio (0.7x) compared to the US Biotechs industry average (1.4x).


Future Growth

How is Cyclerion Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-30.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CYCN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CYCN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CYCN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CYCN's revenue (76.4% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: CYCN's revenue (76.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CYCN's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Cyclerion Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


15.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CYCN is currently unprofitable.

Growing Profit Margin: CYCN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CYCN is unprofitable, but has reduced losses over the past 5 years at a rate of 15.9% per year.

Accelerating Growth: Unable to compare CYCN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CYCN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: CYCN has a negative Return on Equity (-138.32%), as it is currently unprofitable.


Financial Health

How is Cyclerion Therapeutics's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: CYCN's short term assets ($42.8M) exceed its short term liabilities ($9.5M).

Long Term Liabilities: CYCN has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: CYCN is debt free.

Reducing Debt: CYCN had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CYCN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CYCN has less than a year of cash runway if free cash flow continues to grow at historical rates of 11.9% each year.


Dividend

What is Cyclerion Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CYCN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CYCN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CYCN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CYCN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CYCN has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Peter Hecht (57 yo)

3.08yrs

Tenure

US$108,220

Compensation

Dr. Peter M. Hecht, Ph D., served as the Chief Executive Officer of Ironwood Pharmaceuticals, Inc. since 1998 until April 1, 2019. Dr. Hecht is Chief Executive Officer and Director of Cyclerion Therapeutic...


CEO Compensation Analysis

Compensation vs Market: Peter's total compensation ($USD108.22K) is below average for companies of similar size in the US market ($USD770.21K).

Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CYCN's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: CYCN's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.3%.


Top Shareholders

Company Information

Cyclerion Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Cyclerion Therapeutics, Inc.
  • Ticker: CYCN
  • Exchange: NasdaqGS
  • Founded: 2018
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$24.548m
  • Shares outstanding: 43.45m
  • Website: https://www.cyclerion.com

Number of Employees


Location

  • Cyclerion Therapeutics, Inc.
  • 245 First Street
  • 18th Floor
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/15 00:00
End of Day Share Price2022/05/13 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.